NIDDK’s Diabetes Control & Complication Trial
Study group on the trial is scheduled to meet in early June; the trial could be ended early due to favorable results, which might be reported as soon as this year's American Diabetes Association meeting June 12-15. Amylin Pharmaceuticals Chairman Howard Green predicts at Alex. Brown conference that the DCCT trial will draw increased attention to glucose control as a means of avoiding the onset of retinopathy but will highlight the risk of hypoglycemia. Green maintains that amylin replacement therapy is the only glucose control treatment in clinical trials that directly addresses this risk.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth